Bioenergetic and early treatment response stratification (BIOERES): a two-variable prognostic model for early identification of treatment-resistance schizophrenia


Por: Giné-Servén, E, Boix-Quintana, E, Ballesteros, A, Daví-Loscos, E, Guanyabens, N, Casado, V, Silles, S, Toll, A, Campana, M, Cuesta, MJ and Labad, J

Publicada: 31 mar 2026
Resumen:
Approximately one-third of patients with first-episode schizophrenia-spectrum disorders develop treatment-resistant schizophrenia (TRS) within five years, yet reliable early predictors remain lacking. Routine cerebrospinal fluid (CSF) biomarkers may offer insights into TRS pathophysiology and enable early prognostic stratification. In this longitudinal study, we examined whether baseline CSF parameters-total protein, glucose, and lactate dehydrogenase (LDH)-predicted TRS, defined according to TRRIP consensus criteria and clozapine use. Forty-four patients with first-episode schizophrenia spectrum disorders underwent lumbar puncture during index hospitalization and were followed clinically for five years at the Matar & oacute; Mental Health Care Centre. TRS status was confirmed through detailed electronic health record review. Thirteen patients (29.5%) met TRS criteria. At baseline, these individuals had significantly lower CSF LDH concentrations compared to non-TRS patients (p = 0.014), while glucose and protein levels showed no significant differences. In adjusted logistic regression models, lower LDH remained independently associated with TRS (OR = 0.043, p = 0.031). A combined model incorporating LDH and early antipsychotic response achieved an AUC of 0.86, outperforming LDH alone (AUC = 0.73), and demonstrating good discriminative accuracy. Lower baseline CSF LDH concentrations predicted treatment resistance at five years, especially when combined with poor early antipsychotic response. This two-variable prognostic model-BIOERES (Bioenergetic and Early Response Stratification)-may facilitate early identification of high-risk patients and support personalized treatment strategies. Validation in larger, independent cohorts is needed.

Filiaciones:
Giné-Servén, E:
 Hosp Univ Navarra, Dept Psychiat, Pamplona, Spain

 Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain

 Univ Barcelona UB, Fac Med & Ciencies Salut, Barcelona, Spain

Boix-Quintana, E:
 Univ Autonoma Barcelona, Hosp Univ Mataro, Consorci Sanitari Maresme, Dept Mental Hlth & Addict, Mataro, Spain

Ballesteros, A:
 Hosp Univ Navarra, Dept Psychiat, Pamplona, Spain

 Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain

Daví-Loscos, E:
 Univ Autonoma Barcelona, Hosp Univ Mataro, Consorci Sanitari Maresme, Dept Mental Hlth & Addict, Mataro, Spain

Guanyabens, N:
 Univ Autonoma Barcelona, Hosp Univ Mataro, Consorci Sanitari Maresme, Dept Neurol, Mataro, Spain

Casado, V:
 Univ Autonoma Barcelona, Hosp Univ Mataro, Consorci Sanitari Maresme, Dept Neurol, Mataro, Spain

Silles, S:
 Univ Autonoma Barcelona, Hosp Univ Mataro, Consorci Sanitari Maresme, Dept Mental Hlth & Addict, Mataro, Spain

:
 Univ Autonoma Barcelona, Hosp Univ Mataro, Consorci Sanitari Maresme, Dept Mental Hlth & Addict, Mataro, Spain

Campana, M:
 Heinrich Heine Univ, LVR Hosp, Dept Gen Psychiat 2, Dusseldorf, Germany

Cuesta, MJ:
 Hosp Univ Navarra, Dept Psychiat, Pamplona, Spain

 Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain

:
 Univ Barcelona UB, Fac Med & Ciencies Salut, Barcelona, Spain

 Univ Autonoma Barcelona, Hosp Univ Mataro, Consorci Sanitari Maresme, Dept Mental Hlth & Addict, Mataro, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain
ISSN: 21583188





Translational Psychiatry
Editorial
Nature Publishing Group, CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 16 Número: 1
Páginas:
WOS Id: 001731430900002
ID de PubMed: 41916948
imagen Green Submitted, gold

MÉTRICAS